Dourte Marion, Paître Esther, Bouchoucha Mongia, Boyer Emilien, Tomé Sandra O, Doeraene Emilie, Huart Caroline, Leroy Karelle, Thal Dietmar Rudolf, Decottignies Anabelle, Hanseeuw Bernard, Suelves Nuria, Kienlen-Campard Pascal
Aging and Dementia Group, Cellular and Molecular Division (CEMO), Institute of Neuroscience (IoNS), UCLouvain, Brussels, Belgium.
Laboratory for Neuropathology, Department of Imaging and Pathology, Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.
Acta Neuropathol. 2025 Jun 19;149(1):64. doi: 10.1007/s00401-025-02902-6.
Olfactory impairment is a recognized early indicator of neurodegenerative diseases (NDs), such as Alzheimer's disease (AD). Intracellular aggregates of hyperphosphorylated tau protein, referred to as neurofibrillary tangles (NFTs), are a hallmark of AD. NFTs are found in the olfactory bulb (OB) and entorhinal cortex (EC), both crucial for processing olfactory information. We explored the hypothesis that typical tau lesions could appear early and progress along olfactory regions to reach connected areas critically affected in AD (e.g., EC and hippocampal formation). To that end, we used transgenic PS19 mice expressing mutated human tau protein (1N4R isoform, P301S mutation). They recapitulate major phenotypes of AD, such as accumulation of NFTs, synaptic dysfunction, cognitive impairment, and neuronal loss. The presence of pathological hyperphosphorylated human tau protein (pTau) was monitored in olfactory regions: olfactory epithelium (OE), OB, piriform cortex (PC), and in connected regions of the hippocampal formation (hippocampus and EC). pTau was detected in the OE's middle stratum and in the OB's olfactory nerve layer (ONL) at 1.5 months. At 6 months of age, tau accumulations were found in the PC and EC, along with the CA3 region and dentate gyrus of the hippocampus. We found that olfactory function remained unaffected in PS19 mice, despite the presence of tau pathology in key regions of the olfactory system. Targeted treatments (ZnSO and AAVs) were applied at the OE level to assess the impact on tau pathology in the CNS. Complete stripping of the OE by intranasal administration of ZnSO led to a significant reduction in pretangle-like tau pathology within the PC, amygdala, and EC of 6-month-old PS19 mice. Finally, we observed in human postmortem samples that pTau signal was present in the olfactory regions (OE and OB) of patients at early Braak stages (I/II). Based on these observations, we propose that pTau could appear, due to aging or environmental agents, in the OE and subsequently spread in a prion-like manner to the hippocampal formation along neuroanatomical connections. These findings also indicate the interest of the OE as a target for intervention aimed at mitigating the progression of tauopathy in the CNS.
嗅觉障碍是神经退行性疾病(NDs)如阿尔茨海默病(AD)公认的早期指标。过度磷酸化tau蛋白的细胞内聚集体,即神经原纤维缠结(NFTs),是AD的一个标志。NFTs存在于嗅球(OB)和内嗅皮质(EC)中,这两个区域对嗅觉信息处理至关重要。我们探讨了这样一种假说,即典型的tau病变可能早期出现,并沿着嗅觉区域进展,以到达AD中受到严重影响的相连区域(如EC和海马结构)。为此,我们使用了表达突变型人tau蛋白(1N4R异构体,P301S突变)的转基因PS19小鼠。它们重现了AD的主要表型,如NFTs积累、突触功能障碍、认知障碍和神经元丢失。在嗅觉区域监测病理性过度磷酸化人tau蛋白(pTau)的存在:嗅上皮(OE)、OB、梨状皮质(PC)以及海马结构的相连区域(海马和EC)。在1.5个月时,在OE的中层和OB的嗅神经层(ONL)检测到pTau。在6个月大时,在PC和EC以及海马的CA3区域和齿状回中发现了tau聚集。我们发现,尽管嗅觉系统的关键区域存在tau病理,但PS19小鼠的嗅觉功能仍未受影响。在OE水平应用靶向治疗(ZnSO和腺相关病毒)来评估对中枢神经系统中tau病理的影响。通过鼻内给予ZnSO完全剥脱OE导致6个月大的PS19小鼠的PC、杏仁核和EC内的前缠结样tau病理显著减少。最后,我们在人类尸检样本中观察到,在Braak早期阶段(I/II)患者的嗅觉区域(OE和OB)存在pTau信号。基于这些观察结果,我们提出,由于衰老或环境因素,pTau可能在OE中出现,随后以朊病毒样方式沿着神经解剖连接扩散到海马结构。这些发现还表明,OE作为旨在减轻中枢神经系统中tau病变进展的干预靶点具有重要意义。